Clinical trials: Ocular Discomfort
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 2 (NCT02819284)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 62 sites in United States
- Volunteers
- 909 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Syndromes
Investigation of Preservative-Free Ophthalmic Solution in Ocular Dryness
This is a multicenter, prospective, observational, open-label, non-interventional study evaluating the clinical performance and the safety of 4 daily instillations of the ophthalmic solution in the treatment of eye discomfort, in…
- Trial name
- NCT05778942
- Testing
- Eyestil SYNFO
- Where
- 4 sites in Spain
- Volunteers
- 35 people
- Sponsor
- SIFI SpA
Dry Eye Disease (DED)
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
This is a Phase 2, randomized, multicenter, double masked, vehicle controlled, parallel group study to evaluate the efficacy and safety of DFL24498 topical ophthalmic solution versus vehicle in participants with dry eye disease.
- Trial name
- NCT07503886
- Testing
- DFL24498, Vehicle
- Where
- 24 sites in United States
- Volunteers
- 417 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye, Dry Eye Syndromes
Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye
Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time.
- Trial name
- NCT03417505
- Testing
- Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tangible Science
Dry Eye
LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
The purpose of this study is to evaluate the efficacy of LME636 compared to vehicle in the reduction of ocular symptoms and to evaluate the safety and tolerability of LME636, when administered topically for up to 42 days, in…
- Trial name
- NCT02365519
- Testing
- LME636 ophthalmic solution, LME636 Vehicle
- Volunteers
- 514 people
- Sponsor
- Alcon, a Novartis Company
Post Laser Vision Correction Pain and Discomfort
Laser Vision Correction Use of an Eye Shield for Maintaining Vision and Mitigating Pain
The purpose of this research is to determine if an investigational thin shield can effectively reduce discomfort following Laser Vision Correction.
- Trial name
- NCT01675375
- Testing
- Eye Shield
- Where
- 5 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- FORSIGHT Vision3
Dry Eye Disease
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
- Trial name
- NCT01276223
- Testing
- Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
- Where
- United States
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Alcon Research